Le Lézard
Classified in: Health, Business
Subjects: FNC, PDT

Fidmi Medical Launches U.S. Sales of Novel Low-Profile PEG Device and Raises $2.2 Million


CAESAREA, Israel, Oct. 11, 2021 /PRNewswire/ -- Fidmi Medical Ltd. (www.fidmimedical.com) has announced completion of a $2.2 million financing round and launched its FDA-cleared low-profile Percutaneous Endoscopic Gastrostomy (PEG) device in the U.S. Investors in the round include leading medical technology company Micro-Tech (Nanjing) Co., Ltd. (688029: Shanghai), The Trendlines Group (www.trendlines.com), (SGX: 42T) (OTCQX: TRNLY), and Agriline. Micro-Tech has been named Fidmi's exclusive distributor in the U.S. (www.mtendoscopy.com) and China.

Gastrostomy tubes, which help patients receive long-term nutritional support, are typically placed endoscopically and are replaced every 3-6 months. Complications such as clogging and dislodgement are common, resulting in inadequate nutrition and medication delivery, numerous tube replacements, and hospitalizations, all at substantial cost to patients and the health care system.

Within this $800 million market, Fidmi Medical's innovative low-profile gastrostomy system can be utilized for both initial placement and replacement and is more durable and comfortable for patients. Fidmi's improved low-profile gastrostomy tube has a replaceable inner tube that can easily be changed by patients without the assistance of medical professionals and a highly stable internal bumper that is resistant to accidental dislodgement. These features are expected to result in fewer complications, reducing healthcare costs for payers and healthcare systems. The Fidmi PEGs will provide a substantial improvement in quality of life for patients and their caregivers. 

Fidmi Medical CEO Shahar Millis remarked, "We are truly excited to embark on the market entry phase for Fidmi. With FDA clearance and strategic collaboration with Micro-Tech, a leader in this field, we are well-positioned to make a real difference for people requiring long-term nutritional support."

"Together, we saw the opportunity to distribute a device that positively impacts patients and helps them get back to living their lives. We worked quickly to align on a distribution plan that allows the system to be accessible by more physicians ? meeting their needs for more efficient and higher quality patient care, all while tangibly reducing the cost," said Chris Li, President of Micro-Tech Endoscopy USA. "We are proud to partner with Fidmi and applaud their success in improving patient quality of life."

About Fidmi Medical

Fidmi Medical is an Israeli medical device company dedicated to developing enhanced feeding devices that offer easy insertion, replacement, and removal. Fidmi is a portfolio company of The Trendlines Group.

About Micro-Tech Endoscopy USA

Micro-Tech Endoscopy is focused on creating top-quality products for endoscopic diagnosis, and therapeutic medical devices that allow physicians to provide the highest level of care. By partnering with doctors dedicated to innovation, Micro-Tech is committed to bringing better devices to market, with unparalleled speed, at an economical price, and without the burden of contracts.

Contact:
Fidmi Medical
Shahar Millis, CEO, Fidmi Medical Ltd.
[email protected]
+972-77-3628362

Micro-Tech Endoscopy USA, Inc.
Stephanie Reynolds / Emmie McMinn
[email protected]
[email protected]

SOURCE Fidmi Medical Ltd.


These press releases may also interest you

at 14:20
The global gastroesophageal reflux disease (GERD) market  size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.2%  during the forecast period.  Rising geriatric...

at 12:48
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...



News published on and distributed by: